AI assistant
Revenio Group Oyj — Director's Dealing 2016
Dec 1, 2016
3236_rns_2016-12-01_5474d317-5b72-42c7-a303-5a503d27e243.html
Director's Dealing
Open in viewerOpens in your device viewer
Revenio Group Corporation: Managers' transactions
Revenio Group Corporation: Managers' transactions
Revenio Group Corporation: Managers' transactions
December 1, 2016 at 09:05
Person subject to the notification requirement
Name: Bocap Investment Oy Legal Person
Position: Closely associated person
Person discharging managerial responsibilities in issuer
Name: Kakkonen, Kyösti
Position: Member of the Board/Deputy member
Initial Notification
Reference number: 743700I27E0FWSXLKK04_20161130130506_5
Issuer
Name: Revenio Group Oyj
LEI: 743700I27E0FWSXLKK04
Transaction details
Transaction date: 2016-11-28
Venue: NASDAQ HELSINKI LTD (XHEL)
Nature of the transaction: Disposal
Instrument: Share
ISIN: FI0009010912
Volume: 4800
Unit price: 25.49000 Euro
Aggregated transactions
Volume: 4800
Volume weighted average price: 25.49000 Euro
For further information, please contact: Robin Pulkkinen, CFO, +358 50 5059932
DISTRIBUTION:
Nasdaq Helsinki
www.revenio.fi
The Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose
worldwide success is based on a strongly patented intraocular pressure
measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio
Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The
common denominators of Revenio's business operations include screening, follow-
up and the global need to make cost savings through preventive health care.
Revenio seeks vigorous growth in health technology. Revenio aims to develop even
more efficient and easily adopted methods for the early-stage detection of
diseases with significance for public health. The focus of Revenio's screening
technology is on the early detection of glaucoma, osteoporosis, skin cancer and
asthma, and the monitoring of these during the treatment process.
In 2015, Revenio Group's net sales totaled MEUR 20.3, with its operating margin
for continuing operations standing at 28.4%. Revenio Group Corporation is listed
on Nasdaq Helsinki.
[]